Patient Journey With Advanced Lung Cancer Positive for ALK Fusion in Brazil
Completed
- Conditions
- Carcinoma, Non-Small-Cell Lung
- Registration Number
- NCT04947683
- Lead Sponsor
- Latin American Cooperative Oncology Group
- Brief Summary
Observational, retrospective cohort study that will include patients diagnosed with NSCLC and ALK rearrangement between January 2015 and December 2020.
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- COMPLETED
- Sex
- All
- Target Recruitment
- 101
Inclusion Criteria
- Patients older than 18 years;
- Newly diagnosed advanced stage IIIB-IV NSCLC (AJCC 8th edition) or locally advance/distant relapse in the period of January 2015 to December 2020.
- NSCLC with pathological confirmation of ALK rearrangement by immunohistochemistry, fluorescent in situ hybridization (FISH) or next generation sequencing (NGS);
- ECOG 0-4;
- Patients with CNS metastases are also considered eligible, regardless of the initial treatment instituted.
Exclusion Criteria
- Incomplete medical chart in terms of date of diagnosis, ALK test results and outcomes
Study & Design
- Study Type
- OBSERVATIONAL
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method - Describe the treatment sequencing of ALK positive advanced NSCLC in a real-world setting. December of 2020 - Describe the timelines from the appearance of symptoms, histopathological diagnosis, application of the molecular test, and start of treatment. December of 2020
- Secondary Outcome Measures
Name Time Method - Estimate the progression-free survival of first-line treatment, and other subsequent lines; December of 2020
Trial Locations
- Locations (5)
CPO Pucrs
🇧🇷Porto Alegre, RS, Brazil
Liga Norte Riograndense Contra o Câncer
🇧🇷Natal, Rio Grande Do Norte, Brazil
Centro Regional Integrado de Oncologia (CRIO)
🇧🇷Fortaleza, Ceará, Brazil
Instituto D'OR
🇧🇷Rio De Janeiro, RJ, Brazil
A.C Camargo Cancer Center
🇧🇷São Paulo, Brazil